Mr. Herzich is the Chief Technology Officer and leads technology and manufacturing activities across all Solid programs.
Mr. Herzich has served as the Chief Technology Officer of Solid Biosciences, a gene therapy company, since December 2022. Mr. Herzich served as the Chief Technology Officer for AavantiBio from April 2021 to December 2022.
Prior to joining AavantiBio, Mr. Herzich previously served as Vice President, CMC at BridgeBio Pharma, Inc., a biopharmaceutical company, from August 2020 to April 2021. Previously, Mr. Herzich served as Head of Manufacturing Operations at BridgeBio from July 2019 to July 2020. Prior to joining BridgeBio, Mr. Herzich served as Senior Director of Manufacturing at LogicBio Therapeutics, Inc., a genetic medicine company, from January 2018 to July 2019. Mr. Herzich served as Senior Manager and Director of cGMP Gene Therapy Manufacturing at Bamboo Therapeutics (acquired by Pfizer) from August 2016 to January 2018. From July 2015 to August 2016, Mr. Herzich served as the head of TD manufacturing from CSL Seqirus, a pharmaceutical company, and from December 2007 to July 2015, Mr. Herzich served in various roles at CSL Seqirus (acquired by Novartis Vaccines and Diagnostics, Inc.), a pharmaceutical manufacturing company. Mr. Herzich holds a Master of Business Administration from North Carolina State University Poole College of Management and a Bachelor of Science in Biology from Rutgers University.